Replies to post #142694 on Biotech Values

[mcbio]

I would assume someone would want to see more mature data first. I know I would.

Agreed. As such, perhaps 1H13 is the likely goal for a partnership.

In the hands of a bigger, experienced company, they can have more comprehensive development plan, not just in this highly refractory patient population.

Yep, and 011 would presumably be explored in other indications too, namely melanoma given prior results.